Drug Discount Fights in Limbo Until Biden Restores Review Board

A long-awaited venue for resolving drug price fights that jump-started in the Trump administration’s waning days is back on hold as low-income health providers wait for a green light from team Biden.

Until the Department of Health and Human Services appoints new panelists to its drug pricing alternative dispute resolution board, swaths of at-need patients remain unable to afford medications while the hospitals that serve them face steep revenue hits, health centers and the attorneys that represent them say.

“Our plaintiffs need help,” said Barbara Williams, a Powers Pyles Sutter & Verville PC attorney who represented HIV/AIDS clinics in their ...